| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 06/30/2005 | WO2005027881A3 Stable quinapril compositions |
| 06/30/2005 | WO2005021022A3 Stable formulations of peptides |
| 06/30/2005 | WO2005020958A3 Aerosol delivery of curcumin |
| 06/30/2005 | WO2005009329A3 Medicament containing 6-dimethylaminomethyl-1-(3-methoxy-phenyl)-cyclohexane-1,3-diol with delayed release of active ingredients |
| 06/30/2005 | WO2005004840A3 Non-gelatin film and method and apparatus for producing same |
| 06/30/2005 | WO2004110401A3 Inhalation antiviral patch |
| 06/30/2005 | WO2004095921A3 Sporicidal composition |
| 06/30/2005 | WO2004070562A3 System and method for notification and escalation of medical data alerts |
| 06/30/2005 | WO2004070548A3 System and method for verifying medical device operational parameters |
| 06/30/2005 | WO2004017942A8 Inhalation compositions with high drug ratios |
| 06/30/2005 | WO2004017918A9 Method of preparing dry powder inhalation compositions |
| 06/30/2005 | WO2004012710A8 Crystalline drug particles prepared using a controlled precipitation (recrystallization) process |
| 06/30/2005 | US20050143864 Programmable insulin pump |
| 06/30/2005 | US20050143802 Implantable system with drug-eluting cells for on-demand local drug delivery |
| 06/30/2005 | US20050143715 Device for controlled reservoir opening with reinforced reservoir caps |
| 06/30/2005 | US20050143476 Emulsion composite |
| 06/30/2005 | US20050143471 Mixtures of acetaminophen from about 0.1 to about 2.0% (w/w), neutralized carbopol from about 0.18 to about 0.60% (w/w) and polyethylene glycol having high viscocity; sweetening |
| 06/30/2005 | US20050143470 therapeutic treatment of Porcine Respiratory Disease Complex (PRDC) in pigs and Bovine Respiratory Syndrome (BRS) in calves; oral treatment; veterinary medicine |
| 06/30/2005 | US20050143461 inhibiting transmission of sexually transmitted diseases by applying a mixture of suramin sodium and a surfactant; including other active microbiocides, fungicides, viricides, bactericides, antifertility agents |
| 06/30/2005 | US20050143408 Aporphine esters and their use in therapy |
| 06/30/2005 | US20050143404 Solid pharmaceutical dosage formulation |
| 06/30/2005 | US20050143363 Method for subretinal administration of therapeutics including steroids; method for localizing pharmacodynamic action at the choroid of the retina; and related methods for treatment and/or prevention of retinal diseases |
| 06/30/2005 | US20050143361 Compositions for pulmonary administration |
| 06/30/2005 | US20050143342 Administering sulfated polysaccharide such as cellulose sulfate, dextran sulfate, dermatan sulfate, chondroitin sulfate, pentosan sulfate, fucoidin, mannan sulfate, dextrin sulfate, curdlan sulfate, chitin sulfate, heparin or heparin sulfate for therapy and prophylaxis of fungal infection |
| 06/30/2005 | US20050143336 Prevent or reduce inflammation secondary to administration of a lipid-nucleic acid complex in a subject by co-administering a non-steroidal anti-inflammatory agent, a salicylate, an anti-rheumatic agent, an antihistamine, or an immunosuppressive agent with the lipid-nucleic acid complex |
| 06/30/2005 | US20050143324 Compositions and methods for the treatment of inflammatory conditions of mucosae, skin and the eye |
| 06/30/2005 | US20050143321 Characterized by spontaneous increasing of the redox potential in relation to the potential of the hydrogen electrode; used in food industry, medicine, veterinary medicine, pharmaceutical industry, cosmetic industry, balneology, agriculture, fish farming |
| 06/30/2005 | US20050143303 Intranasal administration of glucose-regulating peptides |
| 06/30/2005 | US20050143289 Botulinum toxin pharmaceutical composition |
| 06/30/2005 | US20050143284 Vaccination |
| 06/30/2005 | US20050143283 with a chelating agent; improves the solution stability; lyophilized; antithrombotic agent |
| 06/30/2005 | US20050142636 Culturing yeast transformed with albumin-encoding nucleotide sequence in a fermentation medium; gene expression, separation, conditioning, adding sodium octanoate; cationic exchange chromatography, elution, ultrafiltration, sterilization, diafiltration, filling vessel |
| 06/30/2005 | US20050142531 Drug solution of drug ions and counterions; adjust pH of solution with an ion exchange material; buffer with dipeptides and tripeptides |
| 06/30/2005 | US20050142225 Stabilised pharmaceutical compositions on the basis of polyoxyethlated castor oil and method for manufacturing the same |
| 06/30/2005 | US20050142222 Boehmeria frutescens Thunberg, Boehmeria nivea or the nettle family extracts; without using of toxic organic solvents |
| 06/30/2005 | US20050142218 Therapy of wounds, including skin ulcers and post-operative trauma or burns; allows passage of nitric oxide to the skin |
| 06/30/2005 | US20050142210 Thrombolytic agents and methods of treatment for thrombosis |
| 06/30/2005 | US20050142207 Requires no organic solvents or surfactants so encapsulated biological drugs remain activity during the preparation process; increased recovery yield and encapsulation efficiency of the drugs |
| 06/30/2005 | US20050142206 Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
| 06/30/2005 | US20050142205 Microencapsulation of eg proteins within a polymeric matrix using an emulsion/evaporation process |
| 06/30/2005 | US20050142204 Malaria; encapsulation in animal or plant oil |
| 06/30/2005 | US20050142203 Multi-particulate oral dosage form |
| 06/30/2005 | US20050142202 Allow delivery of a therapeutic substance to a diseased region without significant loss from blood or other fuild flow; simultaneous treatment of multiple regions of a particular lumen or network of lumens |
| 06/30/2005 | US20050142201 Human growth hormone (hGH); liquid-solid phase separation; solid form |
| 06/30/2005 | US20050142200 Antimicrobial concentrates |
| 06/30/2005 | US20050142199 Pharmaceutical dosage forms comprising tablet core having a tensile strength below 38 n/sqcm and a coating to protect the soft core |
| 06/30/2005 | US20050142198 Tablets; reduced side effects; cancer pain; substantially less fentanyl by weight than known oral formulation |
| 06/30/2005 | US20050142197 Generally linear effervescent oral fentanyl dosage form and methods of administering |
| 06/30/2005 | US20050142196 Stable pharmaceutical compositions containing an ACE inhibitor |
| 06/30/2005 | US20050142195 Sealing excipients separate from active materials; tablets, capsules; humidity resistance |
| 06/30/2005 | US20050142194 Chondroitin sulfate (CS); chewable solid, non-compressed; comprises gum arabic and soluble starches as structuring agents |
| 06/30/2005 | US20050142193 Galantamine formulations |
| 06/30/2005 | US20050142191 Pharmaceutical formulations of amyloid inhibiting compounds |
| 06/30/2005 | US20050142190 Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
| 06/30/2005 | US20050142189 administering a hydrophilic alpha-tocopherol ester (especially d- alpha -tocopherol polyethylene glycol 1000 succinate) and paclitaxel; may contain polyethylene glycol or a oxypropylene-oxyethylene glycol nonionic block copolymer. |
| 06/30/2005 | US20050142188 Pellets having a core coated with an antifungal and a polymer |
| 06/30/2005 | US20050142187 Encapsulated amoxicillin is released from stomach to small intestine as particles |
| 06/30/2005 | US20050142186 Capsule comprising low-substituted cellulose ether and method for preparing the same |
| 06/30/2005 | US20050142185 Gelating encapsulated alendronate; bioavailability |
| 06/30/2005 | US20050142184 Emulsion formulations for hydrophilic active agents |
| 06/30/2005 | US20050142182 Long circulating liposome |
| 06/30/2005 | US20050142181 Includes carrier for drug (anticancer agents; anti-sense oligonucleotide against epidermal growth factor receptor) and targeted ligand (benzamide derivative, anisamide) modifying the carrier to target the encapsulated drug to a sigma receptor over-expressed cell |
| 06/30/2005 | US20050142180 Comprises doses of Apolipoprotein A-I Milano:phospholipid complex to reduce and stabilize atherosclerotic plaque; for treating ischemic reperfusion |
| 06/30/2005 | US20050142179 Transfection reagents |
| 06/30/2005 | US20050142178 Comprises doxorubicin hydrochloride for parenteral administration; formed by evaporating solvent from lipid solution comprising phospholipids, sterol and solvent, then hydrating lipid film with aqueous hydration media (ammonium sulfate and sucrose); antitumor agents |
| 06/30/2005 | US20050142177 topical or transdermal anlgesics comprising extracts from shrubs and herbs, glutamine and fat soluble ascorbyl palmitate in the form of vitamin c; antiinflammatory agents |
| 06/30/2005 | US20050142174 Adhesive and binding agent for dermal or transdermal treatment systems |
| 06/30/2005 | US20050142173 Testosterone hydroalcoholic gel for transdermal use; unique pharmacokinetic steady-state profile for testosterone |
| 06/30/2005 | US20050142171 Twisted/cylindrical ribbons; improved mechanical cohesion and smoother outer appearance, without affecting absorption, dilation and gel formation |
| 06/30/2005 | US20050142170 Composition comprising a liquid absorbed on a support based on precipitated silica |
| 06/30/2005 | US20050142167 Soluble highly branched glucose polymers and their method of production |
| 06/30/2005 | US20050142165 coatings selected from retinol, retinal, retinoic acid or p-[(E)-2-(5, 6, 7, 8-tetrahydro-5, 5, 8, 8-tetramethyll-2-naphthyl)propenyl]-benzoic acid, used as grafts for eye tissues; biodegradable prosthetics |
| 06/30/2005 | US20050142162 Soft tissue implants and anti-scarring agents |
| 06/30/2005 | US20050142156 Mono- or di-C-substituted diketopiperazines, e.g., the diketopiperazine of L-Glutamic Acid, are carriers for drug delivery of a wide variety of drugs including biodrugs; oral dosage forms |
| 06/30/2005 | US20050142152 Polymeric materials, their preparation and use |
| 06/30/2005 | US20050142132 Prevention and treatment of amyloidogenic disease |
| 06/30/2005 | US20050142123 Comprising droplets of Coenzyme Q-10 dispersed in a matrix of a modified polysaccharide or a gelatin; supplement for human and animal nutrition |
| 06/30/2005 | US20050142114 Preferentially targeting liposome to mammalian immune cell such as myeloid progenitor cell, monocyte, dendritic cell, macrophage or T-lymphocyte by administering to cell a liposome comprising an active agent and an outer surface that comprises a targeting ligand that binds marker on surface of cell |
| 06/30/2005 | US20050142110 For diagnosis, prevention, or treatment of diseases responsive to therapy with interferon- beta; free of human serum albumin; stability |
| 06/30/2005 | US20050142097 Two different active drugs of same ionic charge conjugated with a single resin particle( cation exchange and anion exchage resin) without displacing the other, and without retarding the initial availability of either active; a barrier cellulose or methacrylic resin coating for controlled release |
| 06/30/2005 | US20050142074 Herbal oro-dental care composition and process for preparing the same |
| 06/30/2005 | US20050142073 Intranasal compositions |
| 06/30/2005 | US20050142072 Drug delivery into nose; controlling concentration into blood; using opioid or non-steroil antiinflammatory dryg |
| 06/30/2005 | US20050142071 Aerosol steroid solution formulation product with enhanced chemical resistance; container equipped with dispensing valve and having a corticosteroid of budesonide, triamcinolone acetonide, and/or rofleponide dissolved; internal surfaces coated with stainless steel, anodized aluminium or inert lining |
| 06/30/2005 | US20050142070 Methods and systems for assessing pulmonary disease with drug therapy control |
| 06/30/2005 | US20050142069 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 06/30/2005 | US20050142063 Detect low frequency surface changes utilizing modified microspheres; exposing surface; microspheres selectively adhere to any targeted surface marker; dislodging adherent microparticles with folic acid; mouthwash for oral cancer detection |
| 06/30/2005 | US20050139808 redox systems for producing oxidized water, used as nontoxic antiseptics against microorganisms, including bacteria, viruses and fungi |
| 06/30/2005 | US20050139211 Introducing aerosol into a ventilator |
| 06/30/2005 | US20050139144 Method for the production and the use of microparticles and nanoparticles by constructive micronisation |
| 06/30/2005 | DE10356095A1 Finishing textiles, e.g. to provide active agent binding or releasing properties, by applying halotriazinyl-substituted cyclodextrin and other functional finishing agent and reacting to cause covalent bonding |
| 06/30/2005 | DE10355904A1 Feste Formen von anti-EGFR-Antikörpern Solid forms of anti-EGFR antibodies |
| 06/30/2005 | CA2552976A1 Multiple section parenteral drug delivery apparatus |
| 06/30/2005 | CA2550505A1 Copper antagonist compounds |
| 06/30/2005 | CA2549916A1 Transdermal delivery system of hormones without penetration enhancers |
| 06/30/2005 | CA2549719A1 Fast-disintegrating tablets |
| 06/30/2005 | CA2549593A1 Stabilised compositions of factor vii polypeptides |
| 06/30/2005 | CA2549197A1 Methods for producing storage stable viruses and immunogenic compositions thereof |
| 06/30/2005 | CA2549038A1 Aqueous suspensions of ciclesonide for nebulisation |
| 06/30/2005 | CA2548387A1 Sustained release torsemide dosage forms |